- |||||||||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment open: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - May 9, 2023 P2b, N=44, Recruiting, Recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | N=600 --> 360 Active, not recruiting --> Recruiting
- |||||||||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies
Enrollment closed: CHAMPION-1: Pertussis Challenge Study in Adults Vaccinated With BPZE1 (clinicaltrials.gov) - May 3, 2023 P2b, N=44, Active, not recruiting, Trial completion date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2024 --> Apr 2024 Recruiting --> Active, not recruiting
- |||||||||| live-attenuated Bordetella pertussis vaccine (BPZE1) / ILiAD Biotechnologies, Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
[VIRTUAL] Serum Bactericidal Activity Induced by Live Attenuated Pertussis Vaccine BPZE1 is Comparable to Boostrix™ () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_2040; SBA-Prn correlations were high post-Boostrix, consistent with prior reports showing Prn is the acellular vaccine antigen that mediates SBA. In contrast, BPZE1 bactericidal antibodies appear broader than Prn which may be important given the global rise of Prn-deficient B. pertussis strains.
|